Results 41 to 50 of about 712 (104)

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

open access: yesMedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng   +9 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ALL

open access: yes
American Journal of Hematology, Volume 101, Issue 8, Page 2038-2043, August 2026.
Sankalp Arora   +18 more
wiley   +1 more source

Collective artificial intelligence and evolutionary dynamics. [PDF]

open access: yesProc Natl Acad Sci U S A
Sehwag UM, McAvoy A, Plotkin JB.
europepmc   +1 more source

Home - About - Disclaimer - Privacy